November 11, 2026

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroze Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir/Madam,

Sub: Apitoria Unit 2, an API manufacturing facility of Apitoria Pharma Private Limited., a subsidiary of the Company, receives Establishment Inspection Report from US FDA with classification as "Voluntary Action Indicated" – Reg.,

Ref: Our letter dated September 15, 2026

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

The United States Food and Drug Administration (US FDA) inspected Unit-II, an API manufacturing facility of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company, situated at Gaddapotharam, Industrial Development Area – Kazipally Industrial Area, Jinnaram Mandal, Sangareddy District, 502319, Telangana from September 7th to September 15th, 2026.

The Unit has now received an Establishment Inspection Report (EIR) classifying the facility as "Voluntary Action Indicated" ("VAI").

FDA has concluded that this inspection is closed under 21 CFR 20.64(d)(3).

Please take the above information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

Digitally signed by ADI REDDY BADDIGAM
Date: 2026.11.11 11:17:27 +05'30'

B. Adi Reddy
Company Secretary